01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

SEC FORM 43h ago

HOUSE PTR3h ago

SEC 13F3h ago

ROBINHOOD CHAIN3h ago

Public company

SRPTSarepta Therapeutics, Inc.

CIK 0000873303

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections3with evidence

SRPT · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
← Lobbied forevidence
MICHAEL BEST STRATEGIES LLCLDA 2T 2026 second quarter · Health issues, MED · Aug 26, 2026
← Lobbied forevidence
TARPLIN, DOWNS & YOUNG, LLCLDA Q1 2026 first quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026

Lobbying

$490K reported · de-duplicated

2026 Q2 $220K in-house2026 Q1 $270K in-house

MICHAEL BEST STRATEGIES LLC$110K2026 Q1 · posted Aug 26, 2026 · Health issues, MED
In-house report$220K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Science/technology, Trade
TARPLIN, DOWNS & YOUNG, LLC$90K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
TARPLIN, DOWNS & YOUNG, LLC$90K2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
MICHAEL BEST STRATEGIES LLC$50K2026 Q2 · posted Aug 26, 2026 · Health issues, MED
In-house report$270K2026 Q1 · posted Aug 26, 2026 · Health issues, Science/technology

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.